Skip to content

The MOG Project Featured by Johns Hopkins Medicine

The MOG Project is honored to be featured by Johns Hopkins Medicine in a recent article highlighting advances in understanding myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and the importance of specialized, collaborative care — particularly for children affected by this rare condition.

The article reflects the mission that has guided The MOG Project since its founding: improving awareness, accelerating research, increasing advocacy, and supporting individuals and families living with MOGAD. The organization was created by family members and advocates, inspired by children like Isabel and Sophia, whose experiences emphasize the urgent need for pediatric-focused research and education.

In the article, the author notes the evolving understanding of MOGAD and how recognition as a distinct disease has advanced in just a few years: “It is now clear that MOGAD was different from multiple sclerosis, though it wouldn’t even have a name until 2018.” That same year, The MOG Project was created. This acknowledgement of MOGAD’s unique clinical identity speaks directly to the importance of The MOG Project’s work.

Founded by Julia Lefelar, alongside Amy Ednie and Kristina Lefelar, The MOG Project works in close partnership with leading clinicians, researchers, and medical centers — including Johns Hopkins Medicine — to advance understanding of MOGAD and improve outcomes for patients of all ages.

We are grateful to the Johns Hopkins team for shining a light on this work and for their continued commitment to pediatric neuroimmunology research and care.

Read the Johns Hopkins features:

This coverage joins a growing body of national and regional media attention highlighting the work of The MOG Project. Our efforts have also been featured by Mayo Clinic, The New York Times, The Washington Post, and local and national news outlets.

To explore more media coverage and learn how awareness, advocacy, and research are moving the field forward, visit our Press page.